Drugs / AD-35
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03790982 | Dec 2018 → Dec 2020 | Alzheimer disease | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03625401 | Oct 2018 → Dec 2020 | early-onset autosomal dominant Alzheimer disease | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03625401 ↗ |
| Route | Oral | “AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.” NCT03790982 ↗ |